As such, it is well-established that ERCC1 expression is altered in several tumor types, including lung, head and neck, and ovarian cancers, suggesting its potential use as a drug target or biomarker for response to platinum-based chemotherapy. The gene discussed is ERCC1; the disease is neoplasm.